Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies.
- DOI
- 10.1007/s10557-026-07954-8
- Published
- 2026 Sep 17
- Container
- Cardiovascular drugs and therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10557-026-07954-8,
title = {Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies.},
author = {Egea G and de Souza RB and Teixidó-Turà G and Mas-Stachurska A and Evangelista A and Loeys B},
year = {2026},
journal = {Cardiovascular drugs and therapy},
doi = {10.1007/s10557-026-07954-8},
url = {https://doi.org/10.1007/s10557-026-07954-8}
}RIS
TY - JOUR TI - Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies. AU - Egea G AU - de Souza RB AU - Teixidó-Turà G AU - Mas-Stachurska A AU - Evangelista A AU - Loeys B PY - 2026 JO - Cardiovascular drugs and therapy DO - 10.1007/s10557-026-07954-8 UR - https://doi.org/10.1007/s10557-026-07954-8 ER -
APA
G, E., RB, D. S., G, T., A, M., A, E., & B, L. (2026). Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies.. Cardiovascular drugs and therapy. https://doi.org/10.1007/s10557-026-07954-8
Source records
- pubmed · retrieved 2026-09-25T07:06:09.467Z